There are 3 unrevealed medications which increase life span (31:09 - 31:13)
Here 2022 new supported interventions
Alpha-ketoglutarate (AKG)
Atorvastatin + Telmisartan
Pioglitazone
Methotrexate
Mifepristone
Place your bets
11 Likes
Earlier findings here:
From: https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/supported-interventions
1 Like
I predict:
- Atorvastatin + Telmisartan: We’ve seen a lot of positive data about Telmisartan already for various metabolic effects, but no lifespan data. I see some moderate promising lifespan data on some different statins in various species in DrugAge
- Pioglitazone: Glucose metabolism modulation is a known way to increase longevity somewhat. I can’t find lifespan data on it, but it seems like a good bet.
- Mifepristone is interesting and showed fairly promising effects in female flies 15%-67%. No data in males. Given its antiprogestogen effects I could see it having a significant difference between female and male mice.
The other 2:
- Methotrexate: Mice are prone to cancer so this could increase their lifespan for this reason, and yet I don’t see good results in previous lifespan studies. One decreased lifespan, the other increased by 7%
- AKG already didn’t really do anything in a previous study on mice despite promising data in worms. On DrugAge I see a max of 6% increase.
My initial feeling with these three was Methotrexate due to the cancer connection but I’m leaning more towards Mifepristone after looking further into it.
3 Likes
Probably not Atorvastatin + Telmisartan since these are mice who typically don’t die of heart problems. I believe this combination is by far the best in humans from that list, but probably won’t have a large effect in the ITP.
Guessing AKG is the other one that didn’t work since the previous higher dose didn’t
Pioglitazone is an obvious choice since the other drug in that class showed benefits in mice. The other two must have as well by process of elimination.
3 Likes
I’ve been pushing pioglitazone for a while now. So that. If I need to pick three, off the top of my head methotrexate and mifepristone. To be honest I didn’t expect that many hits though.
2 Likes
Methotrexate is a JAK2 inhibitor. JAK2 inhibition is similar to IL11 inhibition (largely overlapping pathways), which we know is extremely lifespan extending. So at the right dose, Methotrexate should extend lifespan.
Similar situation with pioglitazone. It’s a no brainer life extension drug in mice at the right dose. Two other ppar gamma activators extended mice lifespan (one in ITP).
2 Likes
What was the ppar-gamma compound that extended mice lifespan in the ITP?
Edit: Ok, I had to search a bit and realized it was Mitoglitazone (MIT).
However, I think they called it MSDC-160 on their supported interventions main page list.
Though when you click MSDC-160 it is linked to another pubmed paper that calls it Mitoglitazone (MIT), and no mention of MSDC-160.
Hope that makes sense, and perhaps someone from ITP can change it to match on both pages.
There are thousands of people in the world and in USA who have been on Methotrexate for years. An retrospective epidemiological study may clarify the effect of the medication on longevity.
Don’t know if the studies have been available or AI was needed to identify the medication.
1 Like
By that measure Rapamycin doesn’t extend human life 
Retrospective analysis has pros and cons.
Methotrexate has been used for patients with psoriasis, other skin conditions, other diseases which are not life threatening. Comparison of longevity in such patients with the patients who suffer from the same conditions but treated differently.
I hate to burst everyone’s bubble, but I don’t think he is talking about the 2022 cohort, but the 2021 cohort which they’ve already released the results of. Listen to the clip again and take notice his wording. “14 winners, 11 published and 3 that will be in our next paper”. But there have already been 14 winners listed on the ITP’s supported interventions page:
- Asprin (at 4 months, later in life failed)
- NDGA
- Rapamycin
- 17-a-estradiol
- Acarbose
- Protandim
- Glycine
- Canagliflozin
- Captopril
- Astaxanthin
- Meclizine
- Epicatechin
- Halofuginone
- MSDC-160
(note: duplicates excluded, and rapamycin + acarbose and rapamycin + metformin were also excluded in this list as rapa and acarbose individually increased lifespan and metformin alone failed, so it stands to reason why he would exclude these from the total number of “winners”)
The last 3 were recent (from the 2021 cohort), so maybe they haven’t fully published the results (it’s not published everywhere they intend to have them published). Hence, 11 published and 3 in next paper. The math lines up perfectly with this theory.
Edit: I checked the upload date of the video and it is November 2025. A lot of interviews are posted months after they take place so it could have been from before they even updated supported interventions page on their website. So I’m even more confident in this theory now.
2 Likes
While IL-11 inhibition was very effective in mice, there are good reasons to think it won’t translate much to humans, especially those using typical longevity interventions that overlap with the same pathways. See the IL-11 section in this article:
2 Likes
astaxanthin is the only one u can take without a prescription haha…thats like 13%?
the rest are pretty funky and not like they sell it OTC
if u believe the glynac studies thats 25% or so lifespan extension…glycine gives 5% in itp studies i believe…
Also aspirin and meclizine don’t require an RX but there are reasons not to just take those. Astaxanthin to me is a no brainer. Glycine why not since it’s cheap.
2 Likes
It’s too bad that the dose of astaxaxnthin used in the ITP studies is way above what everyone would take, so the results aren’t practically useful for humans. They would need to test far lower doses.
I believe they are testing lower doses right now in the ITP
1 Like